Curcumin/Turmeric Supplementation on Glycemic Control in Adults With Prediabetes and Type 2 Diabetes: A Systematic Review and Dose–Response Meta‐Analysis
Open Access
- 16 April 2026
- journal article
- review article
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (4)
Abstract
Curcumin and turmeric have demonstrated potential hypoglycemic properties in preclinical studies, but findings from human randomized controlled trials (RCTs) in prediabetes and type 2 diabetes (T2D) are inconsistent. PubMed, Scopus, and Web of Science ISI databases were comprehensively searched until August 2025 (25/08/2025) to find eligible RCTs. Overall effect sizes were estimated based on the random‐effect models and presented as weighted mean differences (WMD) with 95% confidence intervals (95% CI). All analyses were performed using version 17.0 (Stata Corp., College Station, TX, USA). Thirty‐four eligible RCTs (39 treatment arms) were included in this review. Curcumin/turmeric supplementation significantly reduced fasting blood glucose (FBG) (WMD = −10.15 mg/dL; 95% CI: −12.59, −7.72), hemoglobin A1c (HbA1c) (WMD = −0.32%; 95% CI: −0.43, −0.21), fasting insulin (WMD = −0.69 μU/ml; 95% CI: −1.27, −0.12), homeostatic model assessment of insulin resistance (HOMA‐IR) (WMD = −0.46; 95% CI: −0.60, −0.32), and oral glucose tolerance test (OGTT) (WMD = −11.53 mg/dL; 95% CI: −22.68, −0.44) compared to control groups. However, no significant alteration in homeostatic model assessment of β ‐cell function (HOMA‐B) levels was detected, followed by Curcumin or turmeric supplementation in comparison to the control groups. Subgroup analyses indicated that efficacy was modified by health status (T2D vs. prediabetes), dosage (≥ 1 g/day more effective), and formulation. This meta‐analysis revealed that curcumin/turmeric supplementation may improve glycemic control in individuals with prediabetes or T2D. Despite positive findings, significant heterogeneity across studies necessitates caution. Furthermore, future high‐quality RCTs are required to reach a firm conclusion.Keywords
This publication has 73 references indexed in Scilit:
- Turmeric (Curcuma longaL.) volatile oil inhibits key enzymes linked to type 2 diabetesInternational Journal of Food Sciences and Nutrition, 2012
- Curcumin Prevents High Fat Diet Induced Insulin Resistance and Obesity via Attenuating Lipogenesis in Liver and Inflammatory Pathway in AdipocytesPLOS ONE, 2012
- Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed miceWorld Journal of Diabetes, 2012
- Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled studyScandinavian Journal of Urology and Nephrology, 2011
- GRADE guidelines: A new series of articles in the Journal of Clinical EpidemiologyJournal of Clinical Epidemiology, 2011
- Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cellsBiochemical and Biophysical Research Communications, 2009
- Effect of NCB-02, Atorvastatin and Placebo on Endothelial Function, Oxidative Stress and Inflammatory Markers in Patients with Type 2 Diabetes MellitusDrugs in R&D, 2008
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human VolunteersPlanta Medica, 1998
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997